Equity Overview
Price & Market Data
Price: $1.90
Daily Change: +$0.02 / 1.05%
Daily Range: $1.79 - $1.91
Market Cap: $78,850,808
Daily Volume: 818,373
Performance Metrics
1 Week: -6.12%
1 Month: -5.64%
3 Months: 30.50%
6 Months: 4.55%
1 Year: -73.90%
YTD: -2.65%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.